Vanda Pharmaceuticals (VNDA)’ treatment of polycythemia vera was granted FDA orphan designation, according to a post to the agency’s site.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda seeks FDA Commissioner review of Hetlioz generic ruling
- Vanda Pharmaceuticals’ Legal Victory and Potential HETLIOZ Approval Boosts Buy Rating
- Vanda Pharma granted favourable Court ruling over FDA’s Hetlioz approvability
- Strong Buy Rating for Vanda Pharmaceuticals Driven by Growth in Key Product Lines and Promising FDA Decision
- Vanda Pharmaceuticals’ Earnings Call: Growth Amid Challenges